Seeking Alpha

Celsion gets OK for Phase III cancer-drug trial in four countries

  • Celsion (CLSN) receives regulatory clearance to start a Phase III study of its ThermoDox treatment for primary liver cancer in Taiwan, Hong Kong, South Korea and Canada.
  • The company has also applied for approval to conduct trials in the Philippines, Thailand, China and Europe
  • Celsion has already received FDA clearance for the study, whose primary endpoint is overall survival.
  • The company expects to enroll 550 patients globally at up to 100 sites. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs